The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.

Inclusion Criteria:

• Clinical diagnoses of idiopathic thrombocytopenic purpura
• Hormone and immune suppression, splenectomy is invalid

Exclusion Criteria:

• patients had a bad tolerance to rapamycin
• platelet counts < 10*10E9/L during the treatment of rapamycin

35 patients using rapamycin therapy were observed before and after treatment,who did not response to any other administrations including prednisone and immunosuppressive drugs, even splenectomy .